BioLineRx to Report 2025 Annual Results on March 23, 2026

Rhea-AI Summary

BioLineRx (NASDAQ: BLRX) will release audited financial results for the year ended December 31, 2025 on March 23, 2026 before U.S. markets open. Management will host a conference call on the same day at 8:30 a.m. EDT with CEO Philip Serlin.

Investors can join via dial-in (+1-888-281-1167 U.S.; +972-3-918-0685 international) or via a live webcast on the company website. A webcast replay will be posted about two hours after the call; a dial-in replay is available through March 25, 2026.

News Market Reaction – BLRX

-4.12%

1 alert

-4.12% News Effect

-$479K Valuation Impact

$11M Market Cap

0.3x Rel. Volume

On the day this news was published, BLRX declined 4.12%, reflecting a moderate negative market reaction. This price movement removed approximately $479K from the company's valuation, bringing the market cap to $11M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Results date: March 23, 2026 Fiscal year end: December 31, 2025 Conference call time: 8:30 a.m. EDT +5 more

8 metrics

Results date March 23, 2026 Audited results for year ended December 31, 2025

Fiscal year end December 31, 2025 Reporting period for upcoming annual results

Conference call time 8:30 a.m. EDT Management earnings call on March 23, 2026

U.S. dial-in +1-888-281-1167 Access number for live conference call

International dial-in +972-3-918-0685 International access for live call

Replay end date March 25, 2026 Dial-in replay available until this date

U.S. replay dial-in +1-888-295-2634 Phone replay for conference call

International replay dial-in +972-3-925-5904 International phone replay for call

Market Reality Check

Price: $2.63 Vol: Volume 7,429 is below the...

normal vol

$2.63 Last Close

Volume Volume 7,429 is below the 20-day average of 9,912, indicating subdued pre-announcement activity. normal

Technical Shares at $2.67 are trading below the 200-day MA of $3.64 and 65.64% under the 52-week high.

Peers on Argus

Biotech peers show mixed moves: EDSA -6.44%, MTVA -1.23%, PRTG -10.39%, THAR +5....

1 Up 3 Down

Biotech peers show mixed moves: EDSA -6.44%, MTVA -1.23%, PRTG -10.39%, THAR +5.8%, LSTA +0.4%. Momentum scanner flags LGVN +5.8% and several decliners, suggesting broader but directionally inconsistent sector activity.

Previous Earnings date Reports

1 past event · Latest: Nov 18 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Nov 18	Earnings date notice	Neutral	-5.3%	Set Q3 2025 results date and conference call details.

Pattern Detected

The only prior 'earnings date' announcement in the period saw a clearly negative price reaction.

Recent Company History

Recent updates for BioLineRx have focused on GLIX1 development and financial reporting. A prior earnings date release on Nov 18, 2025 preceded Q3 2025 results and a -5.31% move. Around that time, the company expanded its oncology pipeline via a GLIX1 joint venture and secured U.S. patent protection into 2040 and potentially 2044, while reporting Q3 revenue of $0.4M and cash of $25.2M. Today’s announcement similarly schedules a results release and call without providing new financial figures.

Historical Comparison

-5.3% avg move · Previous earnings date scheduling on Nov 18, 2025 coincided with a -5.31% move. This update is a sim...

earnings date

-5.3%

Average Historical Move earnings date

Previous earnings date scheduling on Nov 18, 2025 coincided with a -5.31% move. This update is a similar calendar notice without new financial metrics.

Limited tag history shows recurring calendar notices for financial results and conference calls, with one prior instance in the dataset.

Market Pulse Summary

This announcement sets March 23, 2026 as the date for BioLineRx’s audited 2025 results and outlines ...

Analysis

This announcement sets March 23, 2026 as the date for BioLineRx’s audited 2025 results and outlines an earnings call at 8:30 a.m. EDT. It follows prior practice of pre-announcing reporting dates, as seen with the Q3 2025 results. Investors may focus on how upcoming figures relate to earlier disclosures on cash ($25.2M at September 30, 2025), revenue trends, and GLIX1 development progress when the full report is released.

AI-generated analysis. Not financial advice.

Management to Hold Conference Call at 8:30 a.m. EDT

TEL AVIV, Israel, March 16, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its audited financial results for the year ended December 31, 2025 on Monday, March 23, 2026, before the U.S. markets open.

The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.

To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until March 25, 2026; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

About BioLineRx

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial is expected to initiate in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS.

The Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and developed by Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop motixafortide in metastatic pancreatic cancer (PDAC) and has a Phase 2b PDAC trial currently ongoing under a collaboration with Columbia University.

Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on LinkedIn.

CONTACTS:

United States
Irina Koffler
LifeSci Advisors, LLC
IR@biolinerx.com

Israel
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com

Logo: https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-2025-annual-results-on-march-23-2026-302714539.html

SOURCE BioLineRx Ltd.

FAQ

When will BioLineRx (BLRX) report its 2025 annual results and when is the conference call?

BioLineRx will report audited 2025 results on March 23, 2026 before U.S. markets open. According to the company, the conference call is scheduled for 8:30 a.m. EDT the same day and will include remarks by CEO Philip Serlin.

How can investors access the BioLineRx (BLRX) March 23, 2026 conference call and webcast?

Investors may dial +1-888-281-1167 (U.S.) or +972-3-918-0685 (international) to join the call. According to the company, a live webcast will also be available on the company website's event page for streaming.

Will there be a replay of the BioLineRx (BLRX) conference call and how soon will it be available?

A webcast replay will be posted approximately two hours after the live call ends. According to the company, a dial-in replay will also be available through March 25, 2026 using the provided replay numbers.

Who will present on the BioLineRx (BLRX) conference call on March 23, 2026?

The conference call will feature remarks by Philip Serlin, Chief Executive Officer. According to the company, management will discuss the audited financial results for the year ended December 31, 2025 during the call.

What fiscal period do the BioLineRx (BLRX) March 23, 2026 results cover and are they audited?

The announcement covers the fiscal year ended December 31, 2025 and the results are audited. According to the company, audited financial results for that year will be released before U.S. markets open on March 23, 2026.